Ana S Newton
Overview
Explore the profile of Ana S Newton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henry S, Liosi M, Ippolito J, Menges F, Newton A, Schlessinger J, et al.
ACS Med Chem Lett
. 2022 Nov;
13(11):1819-1826.
PMID: 36385940
Probe molecules that covalently modify the JAK2 pseudokinase domain (JH2) are reported. Selective targeting of JH2 domains over the kinase (JH1) domains is a necessary feature for ligands intended to...
2.
Liosi M, Ippolito J, Henry S, Krimmer S, Newton A, Cutrona K, et al.
J Med Chem
. 2022 Jun;
65(12):8380-8400.
PMID: 35653642
JAK2 is a non-receptor tyrosine kinase that regulates hematopoiesis through the JAK-STAT pathway. The pseudokinase domain (JH2) is an important regulator of the activity of the kinase domain (JH1). V617F...
3.
Henry S, Liosi M, Ippolito J, Cutrona K, Krimmer S, Newton A, et al.
ACS Med Chem Lett
. 2022 May;
13(5):819-826.
PMID: 35586418
The Janus kinase 2 (JAK2) pseudokinase domain (JH2) is an ATP-binding domain that regulates the activity of the catalytic tyrosine kinase domain (JH1). Dysregulation of JAK2 JH1 signaling caused by...
4.
Newton A, Liosi M, Henry S, Deiana L, Faver J, Krimmer S, et al.
Tetrahedron Lett
. 2021 Aug;
77.
PMID: 34393283
Small molecules that selectively bind to the pseudokinase JH2 domain over the JH1 kinase domain of JAK2 kinase are sought. Virtual screening led to the purchase of 17 compounds among...
5.
Newton A, Faver J, Micevic G, Muthusamy V, Kudalkar S, Bertoletti N, et al.
ACS Med Chem Lett
. 2020 May;
11(5):971-976.
PMID: 32435413
Methyltransferase 3 beta (DNMT3B) inhibitors that interfere with cancer growth are emerging possibilities for treatment of melanoma. Herein we identify small molecule inhibitors of DNMT3B starting from a homology model...
6.
Cutrona K, Newton A, Krimmer S, Tirado-Rives J, Jorgensen W
J Chem Inf Model
. 2020 May;
60(9):4403-4415.
PMID: 32383599
With standard scoring methods, top-ranked compounds from virtual screening by docking often turn out to be inactive. For this reason, metadynamics, a method used to sample rare events, was studied...
7.
Liosi M, Krimmer S, Newton A, Dawson T, Puleo D, Cutrona K, et al.
J Med Chem
. 2020 Apr;
63(10):5324-5340.
PMID: 32329617
Janus kinases (JAKs) are non-receptor tyrosine kinases that are essential components of the JAK-STAT signaling pathway. Associated aberrant signaling is responsible for many forms of cancer and disorders of the...
8.
Dawson T, Dziedzic P, Robertson M, Cisneros J, Krimmer S, Newton A, et al.
ACS Med Chem Lett
. 2017 Dec;
8(12):1287-1291.
PMID: 29259749
Coordination of the ammonium group of Lys32 in the active site of human macrophage migration inhibitory factor (MIF) using a 1,7-naphthyridin-8-one instead of a quinoline is investigated. Both gas- and...
9.
Puleo D, Kucera K, Hammaren H, Ungureanu D, Newton A, Silvennoinen O, et al.
ACS Med Chem Lett
. 2017 Jun;
8(6):618-621.
PMID: 28626521
Janus kinases (JAKs) regulate hematopoiesis via the cytokine-mediated JAK-STAT signaling pathway. JAKs contain tandem C-terminal pseudokinase (JH2) and tyrosine kinase (JH1) domains. The JAK2 pseudokinase domain adopts a protein kinase...
10.
Newton A, Deiana L, Puleo D, Cisneros J, Cutrona K, Schlessinger J, et al.
ACS Med Chem Lett
. 2017 Jun;
8(6):614-617.
PMID: 28626520
A competitive fluorescence polarization (FP) assay is reported for determining binding affinities of probe molecules with the pseudokinase JAK2 JH2 allosteric site. The syntheses of the fluorescent and used in...